The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation

Diabetes and Metabolism

Volumn 42, Issue 2, 2016, Pages 77-79

  Monnier, L ^a   Owens, D R ^b   Bolli, G B ^c  

^a UNIV MONTPELLIER   (France)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Accumulation risk; New long acting insulins; Pharmacodynamics

Indexed keywords

GLUCOSE; INSULIN GLARGINE; INSULIN GLULISINE; LONG ACTING INSULIN; LONG ACTING INSULIN GLARGINE; SHORT ACTING INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; BIOLOGICAL ACTIVITY; DIABETIC PATIENT; EVENING DOSAGE; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN TREATMENT; MEAL; PUBLICATION; STEADY STATE; DIABETES MELLITUS; PATHOPHYSIOLOGY;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE;

EID: 84949655882     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2015.11.005     Document Type: Article

References (14)

1. Owens D.R., Matfin G., Monnier L. Basal insulin analogs in the management of diabetes mellitus: what progress have we made?. Diabetes Metab Res Rev 2014, 30:104-119.
2. Porcellati F., Rossetti P., Busciantella N.R., Marzotti S., Lucidi P., Luzio S., et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized crossover study. Diabetes Care 2007, 30:2447-2452.
3. Owens D.R. Insulin preparations with prolonged effects. Diabetes Technol Therap 2011, 13(Suppl. 1):S5-S14.
4. Porcellati F., Bolli G.B., Fanelli C.G. Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther 2011, 13(Suppl. 1):S15-S24.
5. -1. Diabetes Care 2015, 38:637-643.
6. Heise T., Nosek L., Bottcher S.G., Hastrup H., Haahr H. Ultra-long acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012, 14:944-950.
7. Groop L.C., Bonadonna R.C., Del Prato S., Ratheiser K., Zych K., Ferrannini E., et al. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 1989, 84:205-215.
8. Diamond M.P., Thornton K., Connolly-Diamond M., Sherwin R.S., DeFronzo R.A. Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Invest 1995, 2:708-715.
9. Riddle M.C., Bolli G.B., Ziemen M., Muehlen-Bartmer I., Bizet F., Home P., et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014, 37:2755-2762.
10. Yki-Järvinen H., Bergenstal R., Ziemen M., Wardecki M., Muehlen-Bartmer I., Boelle E., et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014, 37:3235-3243.
11. Bolli G.B., Riddle M.C., Bergenstal R.M., Ziemen M., Sestahauska K., Goyeau H., et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015, 1:386-394.
12. Home P.D., Bergenstal R.M., Bolli G.R., Ziemen M., Rojeski M., Espinasse M., et al. New insulin glargine 300 units/mL in people with type 1 diabetes. A randomized phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015, 10.2337/dc15-0249.
13. Bolli G.B., DeVries J.H. New long-acting insulin analogs: from clamp studies to clinical practice. Diabetes Care 2015, 38:541-543.
14. Vora J., Cariou B., Evans M., Gross J.L., Harris S., Landstedt-Hallin L., et al. Clinical use of insulin degludec. Diabetes Res Clin Pract 2015, 109:19-31.